FDA panel backs first-of-its-kind flu vaccine using mRNA technology
Summary
A federal health advisory panel recommended approval of a new flu vaccine made with mRNA technology, the same science used in COVID-19 vaccines. The FDA is reviewing Moderna’s mFlusiva vaccine for people aged 50 and older before the upcoming flu season.Key Facts
- The vaccine is called mFlusiva and is made by Moderna.
- It uses mRNA technology, which was important for COVID-19 vaccines.
- The vaccine targets seasonal flu, especially for older adults.
- Moderna wants full approval for people aged 50 to 64.
- The company seeks temporary authorization for people 65 and older while more tests continue.
- Approval could allow the vaccine to be available before winter flu season.
- The recommendation came from a federal health advisory panel.
- The FDA is the agency responsible for final approval.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.